Vitamin D Compounds in Chronic Kidney Disease
Authors: Suetonia C. Palmer, Jonathan C. Craig, Giovanni F.M. Strippoli
Journal: Annals of Internal Medicine (2008)

Letters17 June 2008Vitamin D Compounds in Chronic Kidney DiseaseSuetonia C. Palmer, MBChB, Jonathan C. Craig, PhD, and Giovanni F.M. Strippoli, PhDSuetonia C. Palmer, MBChBFrom University of Otago, Christchurch, Christchurch 8140, New Zealand.Search for more papers by this author, Jonathan C. Craig, PhDFrom University of Otago, Christchurch, Christchurch 8140, New Zealand.Search for more papers by this author, and Giovanni F.M. Strippoli, PhDFrom University of Otago, Christchurch, Christchurch 8140, New Zealand.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-148-12-200806170-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Like Dr. Scissors, our preference is for clinical practice to be based on randomized, controlled trials. We also recognize that until the required trials are performed, a sensible approach to distilling existing data and informing practice should be used. However, we need to emphasize that our inclusion criteria were not limited to stage V chronic kidney disease and that we searched for trials of any vitamin D compound, including generic over-the-counter products. No trial data were available on the effects of these products, and very few biochemical data were available on any product in stage III or IV ...References1. Palmer SC, McGregor DO, Craig JC, Elder G, Strippoli GF. Vitamin D analogues for treatment and prevention of bone disease in chronic kidney disease. (Protocol). Cochrane Database Syst Rev. 2006;:CD005633. Google Scholar2. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263-76. [PMID: 16431255] CrossrefMedlineGoogle Scholar3. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al; Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13:1307-20. [PMID: 11961019] CrossrefMedlineGoogle Scholar4. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Pagé D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol. 1998;9:1285-92. [PMID: 9644640] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Otago, Christchurch, Christchurch 8140, New Zealand.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMeta-analysis: Vitamin D Compounds in Chronic Kidney Disease Suetonia C. Palmer , David O. McGregor , Petra Macaskill , Jonathan C. Craig , Grahame J. Elder , and Giovanni F.M. Strippoli Vitamin D Compounds in Chronic Kidney Disease Kenneth Scissors Vitamin D Compounds in Chronic Kidney Disease Daniel W. Coyne Metrics 17 June 2008Volume 148, Issue 12Page: 970KeywordsBoneChronic kidney diseaseClinical trialsCohort studiesObservational studiesPhosphorusVitamin D ePublished: 17 June 2008 Issue Published: 17 June 2008 CopyrightCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...